Home ›
Pancreatic Neuroendocrine Pancreatic Cancer Trials ›
NCT06881992
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).
Trial Details
NCT ID NCT06881992
Phase PHASE3
Sponsor Rezolute
Status RECRUITING
Cancer Type Pancreatic Neuroendocrine Pancreatic Cancer
Interventions
Locations (sample) Chicago, Illinois, United States|41.85003,-87.65005 Bethesda, Maryland, United States|38.98067,-77.10026 Boston, Massachusetts, United States|42.35843,-71.05977 Rochester, Minnesota, United States|44.02163,-92.4699 New York, New York, United States|40.71427,-74.00597
Key Eligibility Criteria
The eligibility criteria of all participants must be evaluated by a multidisciplinary team led by the PI, which must include an oncologist Male or female participants of ≥18 years of age who provide written informed consent. Clinical diagnosis of neuroendocrine tumor (NET) (ICT or NICT) with biochemical evidence of tumor hyperinsulinism (hypoglycemia with inappropriatel… Currently requiring IV glucose infusion and/or parenteral nutrition for ≥7 days for the management of refractory hypoglycemia (prior to administrat…
For full eligibility, visit ClinicalTrials.gov .